Healwell AI: The Next Wave in Healthcare Tech?

The short version

Healwell AI stock belongs to HEALWELL AI Inc., a Toronto-based company that sells AI and software for healthcare. It trades on the Toronto Stock Exchange (TSX: AIDX) and over-the-counter in the US as HWAIF. In the second quarter of 2026, it booked C$33.0 million in revenue, which is barely below the previous year. 6.4 million in quarterly profit came from valuation gains, not from day-to-day operations. On 27 October 2026, the shares changed hands at €0.425 on Tradegate in Germany. Here is what sits behind those numbers.

Healwell AI at a glance

Sources: Finanznachrichten for the Tradegate price, Motley Fool Canada for the TSX price and market value, TipRanks for analyst data.

What does Healwell AI actually do?

Healwell calls itself a healthcare AI company built around preventative care. The idea is simple: software that helps doctors spot at-risk patients sooner. Two segments carry the revenue. Healthcare Software brought in C 31.0 million in Q2 (up2%), almost all of it thanks to Orion Health. 

So the AI business is still small. The bet is that tools such as SMART Summary and SMART Search can be sold into Orion's customers around the world. The engine underneath is called DARWEN. A pilot across British Columbia, Ontario and New Brunswick has finished, and Healwell will present the results at the AMIA symposium in Dallas from 7 to 11 November 2026.

Two smaller pieces round it out. WAIDS scans patient records for possible undiagnosed diabetes, and a real-world study on it is complete. Subsidiary VeroSource launched WELL ID, a digital identity for secure access to records and AI tools, which is already rolling out across the WELL Health clinic network.

For a sense of how far medical AI has come, look at Google's MedGemma models. Whether AI will replace doctors is a different debate and does not belong in a stock check.

The numbers: Q2 2026

Healwell reported on 6 August 2026 (see the release on Newsfile). Figures in C$ millions; Q2 means April to June.

Why revenue stalled: in Q2 2025, one-off project work gave a sharp lift. Gross margin slipped because the Data Science & AI segment did more low-margin project work for life-sciences clients.

The half-year view looks better. Revenue rose to C66.2million(up60%)becauseOrionnowcountsforafullsixmonths.OperatingcashflowswungfromminusC9.9 million to plus C4.5million,andthenetlossshrankfromC16.4 million to C$0.45 million. Our own arithmetic: the adjusted EBITDA margin in Q2 was roughly 3.5%. The year-end target is about 10%.

What could move the share price

• Cross-selling into Orion. CEO James Lee reports several SMART Search and SMART Summary upsells to Orion customers. What matters is whether that turns into revenue that sticks.

• The margin target. Healwell aims for about 10% adjusted EBITDA margin by the end of 2026 and sees tailwinds for 2027. Q3 will show whether the plan holds.

• The SpaceX stake. Healwell invested in xAI in May 2024. Since SpaceX acquired xAI in February 2026, the company holds an indirect SpaceX interest, valued at about C23millionon30June2026againstabookvalueofC4.6 million at the end of March. That is roughly a tenth of the market value. A lock-up of up to six months after the IPO still applies; afterwards Healwell plans to sell and strengthen its balance sheet. For background on xAI, see xAI's Grok-in-Telegram deal and the Grok 3 API launch.

• October headlines. Healwell made TIME's 2026 list of the top 500 HealthTech companies and announced twelve scientific presentations at eight conferences. Add a peer-reviewed study on the MyHealthNB app. That helps the brand but does not replace revenue.

How expensive is the stock?

A rough yardstick: market value was about C230millioninlateAugust,andrevenueoverthelasttwelvemonthswasC132.5 million (both per Motley Fool Canada). That gives a price-to-sales ratio near 1.7. For a software company that looks low, but Healwell carries debt from the Orion deal and its profit margin is thin. Cash stood at about C$16.8 million at the last report. The ratio alone says little. It mainly explains why the market wants proof first: steady margins, falling interest costs and cash from the SpaceX stake.

Forecast: what do analysts say?

Even the lowest target was well above the share price at the time. That signals optimism, not a promise. At the end of 2025, targets were far higher (average C$3.16 according to Börse Express), so they have been cut. A serious forecast out to 2040, which some investors search for, does not exist.

Who owns Healwell AI?

The largest shareholder is WELL Health Technologies, the parent company. Börse Express put its stake at about 69% at the end of 2025. Healwell took over the software firm Intrahealth from WELL Health, as BetaKit reported. For the current stake, check the filings on SEDAR+.

What are the risks?

• No growth. Q2 revenue was down 1%, and Data Science & AI fell 28%.

• Shrinking margin. Gross margin of 54% instead of 56%, and adjusted EBITDA cut in half.

• Read the profit with care. The C6.4millionquarterlyprofitsitsagainstC16.2 million of valuation gains.

• Costly financing. Interest and financing costs rose 92% to C$3.3 million a quarter.

• Reliance on WELL Health. A large shareholder can shape price and strategy.

• Small market value. Stocks this size swing hard and spreads are often wide. For a reminder of how risky AI bets can get, see Michael Burry's warning to tech investors.

Buy or wait?

We will not make that call for you. You can watch whether Healwell moves toward a 10% margin in Q3, when the SpaceX shares get sold, what the AMIA pilot delivers in November, and whether recurring revenue keeps rising. Only invest money you can afford to lose, and check announcements directly at Healwell.

These dates are worth a look:

In Canada, the stock trades as AIDX. Many brokers outside Canada offer it, in Germany often via Tradegate. Check fees, spread and currency risk first, because the stock is quoted in Canadian dollars while German venues show euros. To see how health questions are already handled by AI, read our posts on health in ChatGPT and ChatGPT Health. Two market backgrounds: how Satya Nadella turned a father's struggle into AI healthcare and data centers as a service for healthcare.

Frequently asked questions

What is the current Healwell AI stock price? 

On 27 October 2026, it traded at €0.425 on Tradegate around 11:00. On the TSX, it closed at C$0.76 on 28 August 2026.

Where does Healwell AI trade? 

On the TSX as AIDX in Canadian dollars, over-the-counter in the US on OTCQX as HWAIF, and in Germany on Tradegate, among others, as 6H90. ISIN: CA42249X1006. Availability depends on your broker.

Who owns Healwell AI? 

The largest shareholder is WELL Health Technologies, with about 69% at the end of 2025, according to Börse Express. The CEO is James Lee. The current stake is in the filings on SEDAR+.

What is the Healwell AI price target? 

On 11 August 2026, TipRanks listed six Buy ratings and an average target of C1.88,withinarangeofC1.50 to C$2.25. Targets are estimates, not guarantees.

Is Healwell AI profitable? 

Not in a reliable way yet. Q2 net income was C6.4million,drivenbyC16.2 million of valuation gains. Adjusted EBITDA was C1.1 million, and the half year still shows the loss of C 0.45 million.

Sources

Healwell AI, Q2 2026 release (Newsfile, 6 Aug 2026)

Finanznachrichten, Healwell AI

Motley Fool Canada, AIDX

TipRanks

AIDX forecast

BetaKit 

SEDAR+

Healwell AI